William Yetter, MD
Psychiatry · Virginia Beach, VANPI 1346212230
Payments from drug & device makers
Across 902 payments — averaging $345.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$125K
- Alkermes, Inc.$71K
- Supernus Pharmaceuticals, Inc.$38K
- Teva Pharmaceuticals USA, Inc.$34K
- Axsome Therapeutics, Inc.$21K
- E.r. Squibb & Sons, L.L.C.$12K
- plus $11K from 23 others
Across 1 payment — averaging $250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$250
What the payments were for
- Consulting fees$43,25514%
- Speaking & faculty fees$199,77064%
- Travel & lodging$45,91915%
- Food & beverage$22,8437%
- Education$2400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 184 | $125,058 |
| Alkermes, Inc. | 137 | $71,478 |
| Supernus Pharmaceuticals, Inc. | 58 | $37,699 |
| Teva Pharmaceuticals USA, Inc. | 145 | $33,757 |
| Axsome Therapeutics, Inc. | 20 | $21,055 |
| E.r. Squibb & Sons, L.L.C. | 54 | $11,928 |
| Ironshore Pharmaceuticals Inc. | 14 | $4,944 |
| Sunovion Pharmaceuticals Inc. | 127 | $2,394 |
| Johnson & Johnson | 35 | $1,141 |
| AbbVie(2 entities) | 39 | $836 |
| Lundbeck LLC | 14 | $326 |
| Neurocrine Biosciences, Inc. | 16 | $280 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $240 |
| Biogen | 1 | $134 |
| Tris Pharma Inc | 5 | $103 |
| Vanda Pharmaceuticals Inc. | 5 | $101 |
| Otsuka America Pharmaceutical, Inc. | 5 | $94 |
| Shire North American Group Inc | 5 | $86 |
| Jazz Pharmaceuticals Inc. | 4 | $65 |
| Noven Therapeutics, LLC | 4 | $62 |
| Vertical Pharmaceuticals, LLC | 4 | $59 |
| Almatica Pharma LLC | 2 | $45 |
| Neos Therapeutics, LP | 2 | $38 |
| Neuronetics, Inc. | 2 | $35 |
| Merck | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Sage Therapeutics, LLC | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$274,668
- CAPLYTA$122,542
- ARISTADA INITIO$68,627
- QELBREE$36,760
- AUSTEDO$31,150
- Auvelity$20,756
- Jornay PM 20mg capsules (Bottle of 100)$4,655
- COBENFY$1,693
- LYBALVI$842
- SPRAVATO$358
- VRAYLAR$249
- UZEDY$242
- LATUDA$216
- Austedo XR$125
- LONHALA MAGNAIR$113
How this compares
$312,027 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 13 | $183,384 |
| VraylarCariprazine Hcl | 20 | $44,342 |
| Chlorpromazine Hcl | 21 | $24,060 |
| FetzimaLevomilnacipran Hcl | 26 | $15,731 |
| Lurasidone Hcl | 34 | $12,216 |
| TrintellixVortioxetine Hydrobromide | 19 | $8,551 |
| Aripiprazole | 108 | $6,766 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 115 | $4,178 |
| Quetiapine Fumarate | 193 | $3,465 |
| Bupropion XlBupropion Hcl | 111 | $2,827 |
| Duloxetine Hcl | 140 | $2,684 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 49 | $2,496 |
| Divalproex Sodium ErDivalproex Sodium | 62 | $2,396 |
| Buspirone Hcl | 83 | $2,035 |
| Ziprasidone Hcl | 27 | $1,917 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $33,757 | $183,38413 claims |
| AbbVieVraylar, Fetzima | $836 | $60,07346 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $240 | $8,55119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Virginia Beach
- Mark SchreiberVirginia Beach$29K
- Angelina Espinosa GuanzonVirginia Beach$21K
- Maria CenzonVirginia Beach$17K
- Jolie HinnenkampVirginia Beach$12K
- Elizabeth KaminVirginia Beach$11K
- Stephen CunninghamVirginia Beach$10K
- Heather RoweVirginia Beach$10K
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.